We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mobile-Compatible AI-Powered System to Revolutionize Malaria Diagnosis

By LabMedica International staff writers
Posted on 04 Sep 2025

Malaria remains a major health burden in Malaysia, with Plasmodium knowlesi now the leading cause of human cases. More...

Its rapid replication cycle and similarities to other malaria species make timely and accurate diagnosis particularly difficult. In rural clinics, trained parasitologists are scarce, and misidentification is common. To address these gaps, researchers have developed a locally tailored artificial intelligence (AI) system that enhances the accuracy and speed of malaria diagnosis.

The new system, called MalariaCare+, was created by a team at Universiti Malaya (UM, Kuala Lumpur, Malaysia) and uses a graph-enhanced YOLO deep learning model to detect infected red blood cells, even on overlapping or low-quality slides. MalariaCare+ is being tested in collaboration with Universiti Malaysia Sarawak (UNIMAS, Sarawak, Malaysia) and has been integrated into an app tested with blood samples.

Designed for local realities, it is mobile-compatible and acts as a diagnostic assistant rather than a replacement for medical professionals. Early results show the AI providing healthcare workers with reliable “second set of expert eyes,” improving diagnostic accuracy in real-world rural conditions. The system’s design, shaped by input from doctors, technicians, and field researchers, ensures responsiveness to the on-the-ground challenges of malaria detection in Malaysia.

Next steps include adding a stage-specific classifier to identify Plasmodium knowlesi life stages, enabling faster treatment decisions. Planned updates will bring real-time analysis, visual explanations of AI findings, and secure patient history tracking that works even in low-connectivity areas. In addition to diagnosis, MalariaCare+ will be integrated into public health training at UM and UNIMAS, equipping future healthcare workers with both biological and technological expertise.

“This isn’t AI for the sake of it. This is applied intelligence; built with and for the people who deal with malaria on the ground,” said Associate Professor Dr. Khairunnisa Hasikin, project lead at Universiti Malaya. “We trained the AI to see what even the sharpest eyes might miss. It’s not about replacing doctors and clinicians. It’s about giving them a second set of expert eyes when they need it most.”

Related Links:
Universiti Malaya
UNIMAS


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.